Clinical trial

Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC

NCT03074864

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Erlotinib Hydrochloride Normalized identity: erlotinib hydrochlorideView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Targeted Treatment With Intercalated Radiotherapy in EGFR-mutant IIIA/IIIB NSCLC

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2, PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2017-02-27

PhasePHASE2 / PHASE3

Conditions

Non-small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Epidermal Growth Factor Receptorunresolved

Interventions

Erlotinib HydrochlorideDRUG · verified · RxNorm: erlotinib hydrochloride

Sponsors & collaborators

Guangdong Provincial People's Hospitallead sponsor

Mapped research locations

GuangzhouGuangdong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03074864 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.